We provide commercially focused, creative advice on obtaining, enforcing and exploiting intellectual property rights including patents, trade marks and designs to a wide range of clients who enjoy our straight forward approach and flexible working practices.
From its small beginnings in 1867, Mewburn Ellis has grown into a vibrant, outward-looking partnership with innovation at its core. As science and technology continue to transform the way we live, we look forward to a future as positive and successful as our past.
It's business as usual for Mewburn Ellis despite the decision for the UK to end its membership of the EU. We consider the effect of the decision on intellectual property.
Our experience advising a wide range of clients, from UK-based component manufacturers to multi-national vehicle manufacturers, means we can help you develop an appropriate IP strategy to meet your business needs.
With a medtech team including patent attorneys drawn from all technical disciplines, you can rest assured that you will be working with a specialist that truly understands your technology.
The worldwide recognition achieved by our large pharmaceutical team will give you the confidence that your commercially valuable intellectual property is in the best hands.
t: +44 (0)20 7776 5300
t: +44 (0)117 945 1234
t: +44 (0)1223 420383
t: +44 (0)161 247 7722
The start of the Unitary Patent (UP) and the Unified Patent Court (UPC) has been further delayed. The expected target date of 1 December 2017 cannot be maintained and a start date of mid-2018 (or later) is more likely.
The UK takes another step towards ratifying the Unified Patent Court (UPC) Agreement by laying the The Unified Patent Court (Immunities and Privileges) Order 2017 before the UK Parliament.